Clinical Trials Browser

Phase 2/3 × Terminated × pembrolizumab × Clear all

NCT06295809 2026-05-08

INTerpath-007

Phase 2/3 Terminated

Carcinoma, Squamous Cell, Skin Neoplasms

NCT04969861 2023-01-12

BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

Phase 2/3 Terminated

1 enrolled 6 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms